You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddys Lab launches lansoprazole tablets in US

Capital Market 

The drug major on Monday announced the launch of lansoprazole DR orally disintegrating tablets in the US market.

Dr. Reddy's Laboratories' lansoprazole DR orally disintegrating tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100. The product is therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the U.S. Food and Drug Administration (USFDA). Prevacid is a trademark of Takeda Pharmaceuticals U.S.A., Inc.

Lansoprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). According to IMS Health, the Prevacid brand and generic had US sales of approximately $87 million for the most recent twelve months ending in December 2020.

Shares of Dr. Reddy's Laboratories were down 2.18% at Rs 4583 on BSE. Dr Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses -Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.

The company reported a consolidated net profit of Rs 27.90 crore in Q3 FY21 as compared to a net loss of Rs 538.40 crore in Q3 FY20. Net sales during the quarter rose 12.5% YoY to Rs 4,929.60 crore.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 22 2021. 11:55 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU